Member Info for sadoldgit

jenn1800, A lot of people will require a mask. A vaccination is used to prevent infection, of no use when you have contracted it. That is why we have masks in the first place to limit cross contamination!

There will be no one single cure in the foreseeable future.

When will post Covid be?
The Health Care sector is not a small market by any means.
What happens when the virus mutates? Now in most cases a virus mutates to a less harmful form.
Are you suggesting there will be no similar virus in the future which proves to be more serious?
Has infection of Covid from animals to humans been ruled out?
There are many more questions as these are just the tip of the iceberg.
I would hazard a guess, you have bought in here at some time and have sold out.
Regards

The clinical development candidate targets these two validated targets in AML – FLT3 (including clinically relevant FLT3-ITD-TKD mutant forms) and Aurora kinases.
The strategy of dual FLT3 / Aurora inhibition in a single agent has the potential to overcome the need for combination therapies in AML, and is predicted to have improved efficacy
in FLT-ITD+ AML and reduced susceptibility to resistance mediated by both secondary
FLT3-TKD mutations [3] and high levels of FLT3 ligand.

Point of interest here is that FLT3+Aurora overcomes the need for additional therapies. FLT+3 on its own requires additional therapies in combination to be more effective. The Chinese pharma has a bargain!

Regards all

Acute myeloid leukemia (AML) is a heterogeneous and complex disease, and treatments for this disease have not been curative for the majority of patients. In younger patients, internal tandem duplication of FLT3 (FLT3-ITD) is a common mutation for which two inhibitors (midostaurin and gilteritinib) with varied potency and specificity for FLT3 are clinically approved. However, the high rate of relapse or failed initial response of AML patients suggests that the addition of a second targeted therapy may be necessary to improve efficacy. Using an unbiased large-scale CRISPR screen, we genetically identified BCL2 knockout as having synergistic effects with an approved FLT3 inhibitor. Here, we provide supportive studies that validate the therapeutic potential of the combination of FLT3 inhibitors with venetoclax in vitro and in vivo against multiple models of FLT3-ITD-driven AML. Our unbiased approach provides genetic validation for co-targeting FLT3 and BCL2 and repurposes CRISPR screening data, utilizing the genome-wide scope toward mechanistic understanding.

Interesting note here from ICR with regards to FLT3+Aurora

http://commercial.cancerresearchuk.org/sites/default/files/Novel%20dual%20inhibitors%20of%20FLT3%20and%20Aurora%20Kinases.pdf

Study co-leader Professor Michelle Garrett, previously a Team Leader at The Institute of Cancer Research, London, and currently Professor of Cancer Therapeutics at the University of Kent, said:

“Our study shows the potential of targeting DNA replication for adding to the effect of an existing drug that blocks a system that helps respond to DNA damage.

“It’s exciting too that detecting tumours with low levels of B-family DNA polymerases could be used to identify patients most likely to respond to a CHK1 inhibitor, presumably because of natural weaknesses in DNA repair within these cancers.

“The next step is to develop new drug candidates that could be used to target B-family DNA polymerases in combination with the CHK1 inhibitor SRA737, as we have shown that this could open up a potential new therapeutic approach.”

I like the last paragraph! Develop new drugs in combination with the CHK1 Inhibitor SRA737. Surely this statement secures the future of SRA737.

On the PR side I just cannot see why Sareum do not release information like this as they must be aware of it. Good find by Basser.
Regards

SRA737 is well mentioned in the ICR article.

Giltertinib is used for the treatment of AML, It does have some some serious side effects.

Gilteritinib has been repurposed as a potential antiviral drug as a possible application in the treatment of COVID-19; (Aug 2020)

I don't think a takeover is on either. I could not rule one out for sure, but, basically on the same lines as you have stated below Steve.

The subject reply here is not really pertaining 100% to an earlier discussion.

Regards

Hi Lutonnews,
I think you have hit the proverbial nail on the head regarding possibility and probability. That certainly is the fly in the ointment for many here, the new and not so new. The possibility is there in abundance, probability somewhat less so, but I believe gaining traction all the time.
There will be news out of the blue, exactly when that will be, is a little more than educated guesswork
We are involved in 4 compound and 2 have been out licensed and the lack of recent progress with CHK1 is through no fault of Sareum. A little bit of goalpost shifting by CPF and Sierra on that one.

Regards

Good morning Fadec. Regarding Sareum and the advertising of Flt3. Sareum have up until August 2019 advertised FLT3. There last mention of FLT 3 was an October release stating the following:-
'Aurora+FLT3 Inhibitors

While the Company focuses its research resources on completing the preclinical development of its TYK2/JAK1 programmes, it is seeking a licence partner for the Aurora+FLT3 programme and discussions are ongoing with a number of interested parties.'
That was the last ' advertisement as such ' as I understand in October,2019. The next news we hear is the licensing deal of 26th of March,2020. So yes, there will be no more advertising whilst we await outcome whether the unknown Chinese pharma chooses to continue.
Correct me if I am wrong, but, with regards to formulation issues I will remind you that Tim M stated that Sareum themselves 'lacked the bandwidth to resolove' ie finance and expertise but believed the Chinese pharma had the ability to resolve.
Sareum would be in receipt of payments for FLT3 for sales outside of China, should the Chinese successfully develop FLT3.

As for many many years it has been in development for over 7 years now.

Regards

If you were a buyer, what would you be buying? Tyk2 1801 and 1802 coming to the end of preclinical. (Yes we can argue a price)
Flt3 we still cannot say 100% for sure, but a buyer will want to know the situation with regards to the continuation of the development by the Chinese pharma. Future milestones, royalties etc. ( Any uncertainty makes pricing difficult)
The buyer would also want to know the state of play with Sierra and SRA737. ( An RNS of available funds raised to continue development of SRA737 from Sierra and or Sareum)

We also have the Sareum Kinase inhibitor Library platform, How much is that worth? (open to negotiation)

There is also the potential of 1801 for the effective treatment of Covid 19. 1801 may prove extremely beneficial in treating similar illnesses. ( What would be the difference in price between 'it might' or 'it does'?) Pennies to pounds is suggested here).

I am not ruling a TO out. All I am suggesting are loose ends need tying up first, for that to happen. Investors and buyers do not like uncertainty. If there were no uncertainty this SP would be considerably higher than what it is now.

We are getting there with Sierra and their cost cutting, not dilutive SP strategy to progress CHK1. News will be forthcoming with the Chinese pharma in the next 6 weeks. In all honesty I cannot see them ceasing development. They picked up what was once Sareums Jewel in the Crown for next to mothing. First class ADME and very little or no toxicity issues in a compound that achieved 10 out of 10 mice having greater than 98% tumour reduction. If memory serves me correct there were mice ( a couple at least) that had reduced the tumour completely with no recurring tumour after one 28day cycle. In addition there exists the possibility/probability of it is being developed for use in Covid-19.

All in all we must now be on the verge of that 'significant shareholder value' which Tim Mitchell spoke about in June ,2019.

Slowly but surely I believe we are getting there.

Just my thoughts and my own very honest opinion.

Regards all and enjoy what is left of the weekend.

I have taken this abstract from Sept 2016

SAREUM HOLDINGS PLC

(“Sareum” or “the Company”)

Licence agreement for Chk1 Inhibitor CCT245737

Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce that its co-investment partner, the CRT Pioneer Fund, has today licensed exclusive and worldwide rights for the Chk1 inhibitor cancer drug candidate CCT245737 (to be renamed PNT737) to ProNAi Therapeutics, Inc. (NASDAQ: DNAI).

Under the terms of the agreement, an immediate upfront payment of US$7.0 million is due to the co-investment partners and an additional fee of up to US$2.0 million will be payable upon the successful transfer of the two ongoing Phase 1 clinical trials to ProNAi. Additional payments in the aggregate amount of up to US$319.5 million may become payable upon achievement of certain development, regulatory and commercial milestones. ProNAi will also owe high single to low double digit royalties on the net sales of any product successfully developed.

Under Sareum’s agreements with Cancer Research Technology and the CRT Pioneer Fund, Sareum is entitled to 27.5% of these payments. Therefore, Sareum will receive (i) US$1.9 million as an upfront payment, (ii) potential future milestone payments of up to US$88.4 million, some of which are expected to be paid within the next twelve months upon certain development milestones being met and (iii) its share of any sales royalties.
Now, in Nov 2020 we have a renegotiated agreement between the CPF and Sierra
I would hazard a guess here at the three parties ie CPF, CRT and Sareum would have been involved in discussions with regards to renegotiated lower milestone payments. AFAIK you cannot unilaterally change an agreement or contract without the agreement of the other parties.
Regards

Now take 2.8 million off of the sells and add them to the buys and that will give you a more realistic picture.

Look carefully! At 1301 are delayed shown trades. There are 4x 500k trades and a 800k trade circa 1.35. they are shown as sells.
At 1301 the price was 1.30 to 1.35 hence they are buys. Why do people use the word 'actually' completely out of context nowadays?
Regards

I would suggest that there will be some large buys shown at the end of the day. They may even be shown Monday mornining. Was there any need for a company to have their market cap reduced by nigh 40% as a result of yesterdays RNS that informed us that SRRA would be continuing development. The up front milestone reduced considerably but at that same time reassuring us that Sareum should receive a circa 400k milestone payment in the very near future. With news of the Pfizer vaccine similar happened. Sareum is not reliant on Covid-19 as is not its core objective.
The other aspect of course is the funding for SRA. Did Sierra already access to funding prior to , negotiations with CPF in the attempt to provide additional funding for Momoletonib via the reduction in upfront milestone payments.
It would interesting to find out what game plan Sierra have.
Regards

Yes I lived in Rose Cottage for 16 months 68 paces from Popeyes. Getting noisy in Scrabster as they are getting a new harbour which will take over a year, Yes Upper deck is good. unfortunately had more than our share of lockdowns.
Regards

Yes Warthog, Duncansby Head. Very close to John O groats. Around 25 mins drive from Thurso. It really is great scenery up there!.
Regards

Thankyou Warthog and Rebster, All should go well. It will be interesting as was the Nuclear Reactor Testing Establishment for the Royal Navy. It is next door to Dounreay. To be decommissioned. Money is good and 12 months work at least. So happy at the moment as pig in 5 hit. Scenery is great. 114 miles further on from Inverness. Will be keeping an eye here too and will add at these prices. Proper Haggis too!
Regards all

Andy! It is not being pedantic it is just being right, or we have misinformation. We all do it at times. As a solicitor friend of mine many years ago said to me, Read carefully word by word.
Slight drop in the SP but all in all things looking up. It will lead to an income for Royalties further down the line;
I truly wonder if people here realise the potential of SRA737. Developed by CRT one of the finest if not the finest establishments in the world and Sareum who are top notch chemists. Low tox and effective.

Change of topic I have just been offered work at Vulcan in Caithness. Just waiting a start date. I better get my butt into gear and get my house sorted before I move back up.
Regards